Direct Oral Anticoagulants (DOACs) have significantly improved anticoagulation therapy – due to their ease of use, ...

ROCKVILLE, Md. & EDMONTON, Alberta-- ( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing ...

Exelixis, Inc. (Nasdaq: EXEL) today announced updated and final data from CABINET, a phase 3 pivotal trial evaluating ...

One contributing factor to the inconsistent pharmacokinetics of calcineurin inhibitors may be variable expression of functional CYP3A4 enzymes, CYP3A5 enzymes, and PGP efflux pumps. The ...

The Global Volatile Corrosion Inhibitors (VCI) Packaging Market is anticipated to reach a valuation of USD 825.4 million in 2023, driven by the increasing proliferation of electronic devices and ...

Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and ...

STENDRA can potentiate the hypotensive effect of nitrates, alpha blockers, antihypertensives, and alcohol. CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, erythromycin) increase STENDRA exposure.

We should kind of overreact. The Kansas City Chiefs look unstoppable and now have this cadre of young skill-position players that could buoy the offense and accentuate Patrick Mahomes for the next ...